Abstract
Upper limb spasticity develops in ~30% of patients after stroke [1].
Botulinum toxin A (BTA) is considered the main treatment as a focal myorelaxant.
In recent years, combining BTA with early neurorehabilitation, multimodal
stimulation, and local preparations has become an urgent direction

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2025 Mirzaakhmediy Makhliyo, Saidkhujaeva Saida Nabievna, Abdullaev Zafarjon Khikmatillaevich
